A new trade investigation has reignited a protracted dispute regarding the funding of medical innovation, as Washington claims that German patients benefit from reduced costs while Americans bear an unequal share of the financial burden. The Trump administration has initiated this probe to determine whether US businesses and patients are being forced to pay disproportionately higher prices to subsidize lower costs for German consumers. The inquiry, which is expected to conclude in September, is conducted under Section 301 of the 1974 Trade Act and could potentially result in new US tariffs.
This conflict highlights a fundamental divergence in healthcare policy, as Germany utilizes its public health insurance system to regulate prices and ensure affordability, a practice the US views as a market distortion. Berlin maintains that this regulation is a legitimate mechanism for cost containment. According to OECD data, the US and Germany are the world’s top spenders on medicine. In 2023, per-capita spending reached $1,713 in the US compared to $1,158 in Germany.
US Trade Representative Jamieson Greer stated that the investigation aims to determine if the persistent underpayment for innovative drugs by Germany constitutes an unreasonable or discriminatory practice that restricts US commerce. Greer expressed particular concern regarding pending German legislation that could further reduce spending on innovative pharmaceuticals. This effort specifically targets a multi-billion-euro healthcare savings package proposed by German Health Minister Nina Warken, which seeks to secure additional rebates from drug manufacturers.
The impact of these pricing disparities is evident in drugs like Jardiance, an empagliflozin-based medication developed by Boehringer Ingelheim. While German patients on public insurance pay a maximum co-pay of €10, uninsured or privately insured US patients often face a list price of approximately €300 for a 30-tablet supply. Conversely, low-income or elderly Americans on Medicare or Medicaid often pay significantly less. Experts acknowledge that US patients generally pay more for top-shelf medications, often due to a lack of market transparency and structural differences in how prices are negotiated.
Management consultant Susanne Uhlmann noted that German health insurance funds have greater leverage in central negotiations compared to the fragmented US system, where Pharmacy Benefit Managers (PBMs) act as powerful, often opaque, middlemen. The three dominant US PBMs—CVS Caremark, Express Scripts, and Optum Rx—control roughly 80% of the market. While US regulators, including the Federal Trade Commission, have begun cracking down on these entities for anti-competitive practices, Germany continues to require manufacturers to prove added therapeutic value for new drugs before setting prices.
With over 20% of German pharmaceutical exports destined for the US, the industry is highly vulnerable to this diplomatic and economic friction. An analysis from Deloitte suggests that potential US tariffs ranging from 10% to 35% could result in losses between €1.3 billion and €13.4 billion for German exporters. German Chancellor Friedrich Merz has responded calmly, noting that the country is willing to provide information on its federal reimbursement processes, while Minister Warken emphasized that Germany’s strained health insurance funds have little room to absorb higher costs.
